This was recently demonstrated for patients with JAK2 and TET2 double mutated polycythemia vera, where the individuals who had first acquired a JAK2 mutation had a higher risk of thrombosis and responded better to ruxolitinib than those who had first gained a TET2 mutation [37]. The gene discussed is JAK2; the disease is deep vein thrombosis.